RedHill Biopharma (RDHL) Profit After Tax (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Profit After Tax data on file, last reported at $101.2 million in Q2 2023.

• On a quarterly basis, Profit After Tax rose 764.51% year-over-year to $101.2 million in Q2 2023; TTM through Jun 2023 was -$52.9 million, a 54.97% increase from a year earlier, with the FY2025 full-year figure at -$8.1 million, down 2344.44% from the prior year.
• Profit After Tax for Q2 2023 stood at $101.2 million, up from -$50.2 million in the prior quarter.
• Over the last five years, Profit After Tax for RDHL reached as high as $101.2 million in Q2 2023 and fell as low as -$171.1 million in Q4 2021.
• Historically, Profit After Tax has averaged $3666.7 across 5 years, with a median of $16.6 million in 2020.
• Across the five-year window, Profit After Tax slumped 803.28% in 2021 and jumped 764.51% in 2023, its largest moves.
• Year by year, Profit After Tax stood at $11.7 million in 2019, then jumped by 108.12% to $24.3 million in 2020, then slumped by 803.28% to -$171.1 million in 2021, then increased by 18.41% to -$139.6 million in 2022, then surged by 172.52% to $101.2 million in 2023.
• Per Business Quant data, the three most recent Profit After Tax figures were $101.2 million in Q2 2023, -$50.2 million in Q1 2023, and -$139.6 million in Q4 2022.